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Background: Although many of the recently approved genomically targeted therapies have improved outcomes
for patients in non–small-cell lung cancer (NSCLC) with lung adenocarcinoma, little is known about the genomic
alterations that drive lung squamous cell cancer (SCC) and development of effective targeted therapies in lung SCC
is a promising area to be further investigated. Discoidin domain receptor 2 (DDR2), is a novel receptor tyrosine
kinases that respond to several collagens and involved in tissue repair, primary and metastatic cancer progression.
Methods: Expression of DDR2 mRNA was analyzed in 54 lung SCC tissues by qRT-PCR. Over-expression approaches
were used to investigate the biological functions of DDR2 and its’ mutations in lung SCC cells. Conventional Sanger
sequencing was used to investigate the mutations of DDR2 gene in 86 samples. The effect of DDR2 and its’ mutations
on proliferation was evaluated by MTT and colony formation assays; cell migration and invasion was evaluated by
trasnwell assays. Lung SCC cells stably transfected with pEGFP-DDR2 WT, pEGFP-DDR2-S131C or empty vector were
injection into nude mice to study the effect of DDR2 and its’ mutation on tumorigenesis in vivo. Protein and mRNA
expression levels of E-cadherin and MMP2 were determined by qRT-PCR and western blot analysis. Differences
between groups were tested for significance using Student’s t-test (two-tailed).
Results: In this study, we found that DDR2 mRNA levels were significantly decreased in 54 lung SCC tissues compared
with normal lung tissues. Moreover, there were 3 novel DDR2 mutations (G531V, S131C, T681I) in 4 patients and
provide the mutation rate of 4.6% in the 86 patients with lung SCC. The mutation of S131C in DDR2 could promote
lung SCC cells proliferation, migration and invasion via inducing MMP-2, but reducing E-cadherin expression.
Conclusions: These data indicated that the novel DDR2 mutation may contribute to the development and
progression of lung SCC and this effect may be associated with increased proliferation and invasiveness, at least in part,
via regulating E-cadherin expression.
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Lung cancer is the leading cause of cancer death world-
wide, and Non-small cell lung cancer (NSCLC) that in-
cluding adenocarcinoma and squamous cell carcinoma,
is the predominant form of lung cancer [1]. Because of
the limited benefits provided by surgery, chemotherapy,* Correspondence: yong_song6310@yahoo.com
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unless otherwise stated.and radiation, the improvement in prognosis and survival
of patients with lung cancer in the past 20 years is still un-
favorable [2]. Recently, although significant advances have
achieved in the chemotherapy and radiation therapy for
advanced disease patients with NSCLC; however, most pa-
tients will eventually develop resistance. Therefore, there
is a need for better understanding of the genetic abnor-
malities in NSCLC cancers to identify and develop novel
and effective targeted therapies.
To date, analysis of individual patients’ genetic makeup
is becoming more and more important in guiding thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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this is the development of small-molecule inhibitors of the
epidermal growth factor receptor (EGFR) tyrosine kinase
therapies, which resulted in a great deal of progress in the
targeted treatment of patients with NSCLC [3-6]. Somatic
mutations in the EGFR gene play key roles in determining
the sensitivity of NSCLC patients treated with EGFR in-
hibitor drugs; however, most of the patients who respond
to EGFR kinase inhibitors are the adenocarcinoma sub-
type of NSCLC [7]. In contrast, patients with the lung
squamous cell cancer (SCC) which accounts for about
25% of NSCLC very rarely respond to these agents; few
advances have been made in the treatment of this type of
NSCLC [8]. In addition to EGFR, many other promising
therapeutic targets including EML4-ALK, MET and KRAS
have been identified and drugs directed against these
proteins are being tested in clinical trials [9-11]. How-
ever, it appears that these drugs are also likely limited to
lung adenocarcinomas. Given the burden of disease from
lung SCC, identifying new therapeutic targets of mutated
kinases is essential for lung SCCs.
DDR2, a receptor tyrosine kinase that binds collagen I
and III as its endogenous ligand, is known to increase
expression of matrix metalloproteinases and has been pre-
viously shown to promote cell proliferation, migration and
metastasis by regulating epithelial–mesenchymal transi-
tion [12-15]. The altered expression patterns of DDR2
mRNA expression have been reported in multiple types
of human cancer, including NSCLC [16,17]. Moreover,
DDR2 mutations have been noted in several cancer speci-
mens including in NSCLC (R105S, H136H and N456S)
[18,19]. However, these reports have not been confirmed
in independent samples and whether there are novel mu-
tations in Chinese population should be investigated.
In this study, the mRNA levels and mutation status of
DDR2 at the discoidin and kinase domains in lung SCC
was investigated. We found three novel somatic muta-
tions in the DDR2 at a frequency of 4.6% ( n = 4) in a
sample set of 86 lung SCC samples. We also show that
DDR2 mutations are oncogenic via promoting cells prolif-
eration, migration and invasion by exogenous overex-
pression in lung SCC cells. Furthermore, DDR2 mutation
could induce Epithelial-to-Mesenchymal Transition in lung
SCC cells by downregulating E-cadherin expression. These
data indicated that the novel DDR2 mRNA mutation may
contribute to the development and progression of lung
SCC and this effect may be associated with increased prolif-




Lung SCC and normal lung tissues were obtained from
patients who underwent primary surgical resection ofNSCLC with informed consent at Nanjing Drum Tower
Hospital Affiliated to Medical School of Nanjing University
between 2008 and 2011. No local or systemic treatment
had been conducted in these patients before the operation.
All these tissue samples were immediately snap-frozen in
liquid nitrogen and stored at −80°C until total RNA was
extracted. The study was approved by the Research Ethics
Committee of Nanjing Drum Tower Hospital (Nanjing,
Jiangsu, PR China). Informed consent was obtained from
all patients.
Cell lines and culture conditions
NSCLC squamous carcinomas cell lines (SK-MES-1, NCI-
H1703), a normal human bronchial epithelial cell line
(HBE) were purchased from the Institute of Biochemistry
and Cell Biology of the Chinese Academy of Sciences
(Shanghai, China). All cells were cultured in RPMI 1640
(GIBCO-BRL) medium supplemented with 10% fetal bo-
vine serum (10% FBS), 100 U/ml penicillin, and 100 mg/ml
streptomycin (invitrogen) in humidified air at 37°C with 5%
CO2. Cells were grown on 250 ng/ml type I collagen (BD
Biosciences, San Diego, CA) for all relative experiments.
RNA extraction and qRT-PCR analyses
Total RNA was isolated with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
protocol. For analysis of DDR2, E-cadherin, N-cadherin,
MMP-2 and MMP-9 mRNA expression, 500 ng total
RNA was reverse transcribed in a final volume of 10 μl
using random primers under standard conditions using
the PrimeScript RT reagent Kit and SYBR Premix Ex Taq
(TaKaRa, Dalian, China) according to the manufacturer’s
instructions. GAPDH gene was used as an internal control.
The primers were designed as follows: DDR2, forword
primer: 5′-CCACTATGCAGAGGCTGACA-3′ and re-
verse: 5′-CAGAGATGAACCTCCCCAAA-3′; MMP-2,
forword primer: 5′ CGTCTGTCCCAGGATGACATC
3′, reverse primer: 5′TGTCAGGAGAGGCCCCATAG
3′; MMP-9, forword primer: 5′ TGGGCAGATTCCAA
ACCTTT 3′, reverse primer: 5′ TCTTCCGAGTAGTT
TTGGATCCA 3′; E-cadherin, forword primer: 5′ TCC
CATCAGCTGCCCAGAAA 3′, reverse primer:5′ TGA
CTCCTGTGTTCCTGTTA 3′GAPDH, forword primer:
5′ GGGAGCCAAAAGGGTCAT 3′, reverse primer: 5′
GAGTCCTTCCACG ATACCAA 3′. The relative levels
of mRNA expression were calculated based on the differ-
ence between amplification of target genes and GAPDH
mRNA using the 2-ΔΔct method. All experiments were
performed three times with three technical replicates.
DDR2 sequencing
DDR2 was sequenced from DNA obtained from lung
SCC patient samples by conventional Sanger sequencing.
In the discovery set, 86 patient samples were used for
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confirmed as somatic. Mutations were identified using
an automated mutation caller and then verified manually
with comparison made to the matched normal sequence
in the case of all primary tumor samples.
Plasmid constructs
To generate a DDR2 and its mutated transcript expression
vector, the entire sequence of human DDR2 and muta-
tedDDR2 was synthesized and subcloned into pEGFP-N1
vector with incorporate external NheI and BamHI sites,
respectively (Invitrogen, Shanghai, China).
Transfection of lung SCC cells
All plasmid vectors for transfection were extracted by DNA
Midiprep or Midiprep kit (Qiagen, Hilden, Germany). Lung
SCC cells cultured on six-well plate were transfected with
the pEGFP-DDR2, pEGFP-DDR2-S131C, pEGFP-DDR2-
T681I or empty vector using Lipofectamine2000 (Invitro-
gen, Shanghai, China) according to the manufacturer’s
instructions. Cells were harvested after 48 hours for
qRT-PCR and western blot analyses.
Cell proliferation assays
Cell proliferation assay was performed with MTT kit
(Sigma, St. Louis, Mo) according to the manufacturer’s
instruction. Cells were placed into 6-well plate and main-
tained in media containing 10% FBS for 2 weeks for col-
ony formation assay. Colonies were fixed with methanol
and stained with 0.1% crystal violet (Sigma, St. Louis, Mo).
Visible colonies were manually counted.
Cell migration and invasion assays
For the migration assays, 24 hours after transfection, 3 ×
104 cells in serum-free media were placed into the upper
chamber of an insert (8-μm pore size, millepore). For the
invasion assays, 1 × 105 cells in serum-free media were
placed into the upper chamber of an insert coated with
Matrigel (BD, San Diego, CA. Media containing 10% FBS
were added to the lower chamber. After 24 hours of
incubation, the cells remaining on the upper membrane
were removed with cotton wool, whereas the cells that
had migrated or invaded through the membrane were
stained with methanol and 0.1% crystal violet, imaged, and
counted using an IX71 inverted microscope (Olympus,
Tokyo, Japan). Experiments were independently repeated
three times.
Western blotting assay
Cells were lysed using mammalian protein extraction
reagent RIPA (Beyotime) supplemented with protease
inhibitors cocktail (Roche) and PMSF (Roche). Protein
concentration was measured with the Bio-Rad protein
assay kit. 40 μg protein extractions were separated by10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE),
then transferred to 0.22 μm NC membranes (Sigma) and
incubated with specific antibodies. Autoradiograms were
quantified by densitometry (Quantity One software; Bio-
Rad). GAPDH was used as control. GAPDH antibody was
purchased from sigma; Collagen Iand DDR2 antibody
were purchased from Abcam; E-cadherin antibody was
purchased from BD (San Diego, CA); MMP-2 antibody
was purchased from CST.
Tumor formation assay in a nude mouse model
Four weeks old nude mice were used for the tumor for-
mation assay. All of the mice were BALB/c background.
The animal care and experimental procedures were ap-
proved by the Model Animal Research Center of Jingling
Hospital and conducted according to Institutional Animal
Care and User guidelines. H1703 cells stably transfected
with pEGFP-DDR2, pEGFP-DDR2-S131C or empty vector
were resuspended at a concentration of 2 × 107 cells/ml.
Each mouse was injected on the right side of the posterior
flank with 2 × 106 suspended cells. Tumor growth was
measured by calipers every 3 days. The tumors were
removed from all of the animals after 15 days, and the
subcutaneous growth of each tumor was examined.
The tumor volumes were calculated using the equa-
tion V = 0.5 × D × d2 (V, volume; D, longitudinal diam-
eter; d, latitudinal diameter). All of the surgeries were
performed under sodium pentobarbital anesthesia, and
all efforts were made to minimize suffering.
Statistical analysis
Student’s t-test (two-tailed), One-way ANOVA and Mann–
Whitney test were performed to analyze the data using
SPSS 16.0 software. P values less than 0.05 were considered
statistically significant.
Results
Expression of DDR2 mRNA is down-regulated in lung SCC
The expression of DDR2 was detected in 54 lung SCC
samples and normal tissues by qRT-PCR, and normal-
ized to GAPDH. The level of DDR2 mRNA was signifi-
cantly decreased in cancerous tissues (median ratio of
1.76-fold, p < 0.01) compared with corresponding normal
tissues (Figure 1A). Furthermore, correlation analysis of
DDR2 expression with clinical pathological features of
lung SCC patients showed that DDR2 expression was
relatively higher in lung SCC patients with advanced
stage (P = 0.006) and lymph node metastasis (P = 0.009)
(Figure 1B and C). However, DDR2 expression was not
correlated with patient age, gender or other clinicopath-
ological features (data not shown).
Kaplan-Meier survival analysis was performed to further
evaluate the correlation between DDR2 expression and
lung SCC patient prognosis. According to the median ratio
Figure 1 Relative DDR2 expression in lung SCC tissues and its clinical significance. (A) qRT–PCR analysis of the relative DDR2 expression in
lung SCC tissues (n = 54) and in paired adjacent normal tissues (n = 54). DDR2 expression was normalized to GAPDH expression. The data are
presented as a fold-change in the tumor tissue relative to the normal tissue. (B) DDR2 expression was relatively higher in patients with lymph
node metastasis. (C) DDR2 expression was relatively higher in patients with an advanced clinical stage than those with an early clinical stage.
(D) There was no significantly difference in survival times between patients with high DDR2 expression and those with low DDR2 expression
levels *P < 0.05, **P < 0.01.
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56 NSCLC patients were classified into two groups:
High-DDR2 group (n = 27, DDR2 expression ratio ≥me-
dian ratio) and Low-DDR2 group (n = 27, DDR2 expres-
sion ratio ≤median ratio). The Kaplan-Meier survival
curve showed that there was no significantly difference
in survival times between patients with high DDR2 ex-
pression and those with low DDR2 expression levels
(Figure 1D).
DDR2 is mutated in lung SCC
We performed Sanger sequencing of DDR2 gene in an
set of 86 primary lung SCC samples and identified four
synonymous mutations in 7 samples and three novel re-
current somatic mutations (G531V, S131C, T681I) in 4samples in the tyrosine kinase genes: DDR2, resulting
in an overall frequency of 4.6% in 86 total primary lung
SCC samples. Mutations were found both in the kinase
domain and in other regions of the protein sequence
(Figure 2A). The S131C mutation was identified in the
exon5, G531V and T681I mutations were found in
exon13 and exon15, respectively (Figure 2B, C and D).
The majority of the mutations resided in regions of
high degrees of amino acid conservation, compared with
the mouse, and zebrafish homologs of DDR2 (Figure 2E).
A query of the limited clinical information accompany-
ing the sequenced samples did not identify any signifi-
cant correlation of DDR2 mutation status with age,
sex, or smoking status of the patients (Additional file 1:
Table S1).
Figure 2 Detection of DDR2 gene mutation in lung SCC tissues. Conventional Sanger sequencing was performed to analysis the DRR2 gene
mutation. (A) In addition to reported DDR2 mutations, three novel DDR2 muatations were found in chinese lung SCC patients. (B, C and D) The
S131C mutation was identified in the exon5, G531V and T681I mutations were found in exon13 and exon15, respectively. (E) Analyse of amino
acid conservation of DDR2 among human, mouse, and zebrafish homologs.
Figure 3 The effect of DDR2 mutation on lung SCC cells proliferation in vitro. HBE, H1703 and SK-MES-1 cells were transfected with pEGFP-DDR2,
pEGFP-DDR2-S131C, pEGFP-DDR2-T681I or empty vector. (A, B, C) An MTT assay was performed to determine the proliferation of pEGFP-DDR2,
pEGFP-DDR2-S131C, pEGFP-DDR2-T681I or empty vector-transfected HBE, H1703 and SK-MES-1 cells. (D,E) A colony-forming growth assay was performed
to determine the proliferation of pEGFP-DDR2, pEGFP-DDR2-S131C, pEGFP-DDR2-T681I or empty vector-transfected HBE, H1703 and SK-MES-1 cells. The
colonies were counted and captured.
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http://www.biomedcentral.com/1471-2407/14/369DDR2 S131C mutation is oncogenic and promotes lung
SCC cells proliferation in vitro
DDR2 mutations have been found to be associated with
lung SCC cells growth and dasatinib sensitivity. Therefore,
to investigate the potential biological function of these
novel DDR2 mutations in lung SCC cells, we constructed
the DDR2 wild type, S131C and T681I mutated DDR2
expression plasmid vector (pEGFP-DDR2, pEGFP-DDR2-
S131C, pEGFP-DDR2- T681I). Furthermore, MTTassay re-
vealed that cell growth was significantly increased in HBE,
H1703 and SK-MES-1 cells transfected with pEGFP-DDR2-
S131C compared with cells transfected with empty vector,
wildtype pEGFP-DDR2 or pEGFP-DDR2-T681I vector
(Figure 3A, B and C). Similarly, the results of colony-
formation assay also showed that clonogenic survival
was increased following transfection of pEGFP-DDR2-
S131C in HBE, H1703 and SK-MES-1 cells (Figure 3D).
Effect of DDR2 S131C mutation on lung SCC cells
migration and invasion
Recently, DDR2 was reported to be critical for breast
cancer invasion and migration in vitro and for metastasis
in vivo via sustaining SNAIL1 stability and activity to
promote tumor cells migration and invasion throughFigure 4 The effect of DDR2 mutation on lung SCC cells migration an
with pEGFP-DDR2, pEGFP-DDR2-S131C, pEGFP-DDR2-T681I or empty vector
gratory and invasive abilities of cells. *P < 0.05 and **P < 0.01.collagen-I-enriched tumour-associated matrices [15]. To
investigate whether DDR2 mutation could have a direct
functional effect in facilitating lung SCC cell migration
and invasion, we evaluated cancer cell invasion through
matrigel and migration through wound healing and trans-
well assays. As shown in Figure 4A, overexpression of
DDR2 S131C could enhance the ability of migration and
invasion in HBE cells when compared with cells treated
with pEGFP-DDR2 wildtype vector. Similarly, migration
and invasion of H1703 and SK-MES-1 cells was also
increased following transfection of pEGFP-DDR2-S131C
compared with cells transfected with empty vector, wildtype
pEGFP-DDR2 or pEGFP-DDR2-T681I vector (Figure 4B
and C). These data indicated that DDR2 S131C mutation
can promote the migratory and invasive phenotype of lung
SCC cells.
DDR2 S131C mutation promotes lung SCC cells growth
in vivo
To further provide in vivo evidence for the oncogenic
role of DDR2 S131C mutation in lung SCC, we used a
xenograft mouse model. BALB/c mice were subcutane-
ously injected with H1703 cells transfected with pEGFP-
DDR2, pEGFP-DDR2-S131C or empty vector randomly.d invasion in vitro. HBE, H1703 and SK-MES-1 cells were transfected
. (A, B, C) Transwell assays were used to investigate the changes in mi-
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able tumors. Compared to the control treatment, DDR2-
S131C overexpression treatment dramatically increased
tumor growth, which was demonstrated by significantly
increased tumor size and weight (Figure 5A and B). Thus,
DDR2-S131C overexpression promotes the growth of
established lung SCC xenografts. In addition, the HE
staining showed the typical characteristics of tumor cells,
and the proliferation index Ki67 determined by immuno-
histochemical staining significantly upregulated in the pEG
FP-DDR2-S131C transfected tumors (Figure 5C).
DDR2 mutation induced lung cells proliferation and
invasion partly via regulating E-cadherin expression
Firstly, we investigated the total DDR2 protein levels of
H1703 cells after transfection of wildtype or mutated DDR2
and the results that there was no difference in wildtype or
mutated DDR2 transfected H1703 cells. Furthermore, to
investigate whether these mutations affect collagen bind-
ing, we detected the collagen Iprotein level in wildtype or
mutated DDR2 transfected H1703 cells;however, there
was no significantly difference. These data indicated that
the observed phenotypes is not due to differences inFigure 5 DDR2 S131C mutation promotes lung SCC cells growth in vi
pEGFP-DDR2, pEGFP-DDR2-S131C or empty vector and then injected into n
(B) The tumor weight was represented as means of tumor weights ± s.d. (C)
of the proliferation index Ki67.protein expression levels or collagenI binding, which may
be due to receptor phosphotyrosine levels upon acquisi-
tion of mutations.
Epithelial-to-mesenchymal transition (EMT), a funda-
mental biological process in embryonic development, has
been found to be involved in tissue homeostasis, wound
healing, tumor invasion and metastasis [20]. Recent stud-
ies show that transforming Growth Factor-beta1 (TGF-β1)
could promote increased expression of type I collagen and
DDR2 and induce EMT, while knockdown of DDR2 ex-
pression with siRNA inhibits EMT directly induced by
type I collagen [14,21]. Therefore, we investigated whether
the mechanism whereby DDR2 mutation could promote
EMT process in lung SCC cells. The results of qRT-PCR
showed that DDR2 ovexpression could induce the MMP-2
mRNA expression and decrease E-cadherin mRNA expres-
sion, while transfection of pEGFP-DDR2-S131C could in-
duce more significantly changes in E-cadherin and MMP-2
mRNA expression (Figure 6A). Moreover, western blot
analysis also showed the same results (Figure 6B and C).
These data indicated that DDR2 mutation may infuence
lung SCC cells proliferation, migration and invasion via
partly promoting the epithelial-mesenchymal transition.vo. (A) Tumor growth curve. H1703 cells were stablely transfected with
ude mice. The error bars represent the standard deviation (S.D).
Representative images (×200) of HE staining and immunohistochemistry
Figure 6 E-cadherin is key downstream mediator of DDR2 S131C. H1703 cells were transfected with pEGFP-DDR2, pEGFP-DDR2-S131C,
pEGFP-DDR2-T681I or empty vector, respectively. (A) QRT-PCR analysis was performed to determine E-cadherin, N-cadherin, MMP2 and MMP9
expression in H1703 cells. (B, C) E-cadherin and MMP2 protein expression in H1703 cells was determined by western blot analysis. The results are
from 3 independent experiments. GAPDH protein expression was used as an internal control. * P < 0.05; ** P < 0.01.
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Despite the deployment of molecularly targeted agents
leading to great advances in the treatment of lung adeno-
carcinoma and improvements in patient outcomes, little
is currently known about the targetable genetic abnor-
malities underlying lung SCC [22,23]. In addition to TP53
mutations, lung SCC have been shown to harbor amplifi-
cations of SOX2 and EGFR variant III mutations as well
as DDR2 mutations [18,24,25]. In the present study, we
found that DDR2 mRNA expression is significantly down-
regulated in lung SCC tissues when compared with nor-
mal lung tissue. Moreover, 3 novel mutations in exon5, 13
and 15 of DDR2 gene in a screen of 86 lung SCC samples
were identified, yielding an overall mutation rate of 4.6%
in all samples, which indicated that there is no significant
difference of DDR2 mutation rate in Chinese, Europe
and American patients. However, DDR2 mutation doesnot exist concentrated area and missense mutation are
more slightly common in the extracellular domain and
kinase domain. DDR2 have previously been reported to
be involved in various human diseases, including can-
cers [26-28]. Although the sample size was not large,
the novel DDR2 mutations in lung SCC suggest that
DDR2 mutations could contribute to the pathogenesis
of lung SCC.
The mechanism by which DDR2 and its mutations
may contribute to oncogenesis in lung SCC is not well
known; however, given its role in transmitting signals
from the ECM, it is likely that DDR2 could act as regulators
of cell proliferation, migration and subsequent tumor cells
metastasis. Activated DDR2 can induce the expression of
MMP-1, MMP-2 and MMP-13, and stimulation of DDR2
could promote fibroblast migration and proliferation. In
addition, it is conceivable that altered expression of DDRs
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proliferation and oncogenesis as well as EGFR [29-31]. In
this study, DDR2 wildtype overexpression vector and two
DDR2 mutations vector (pEGFP-DDR2-S131C, pEGFP-
DDR2-T681) were constructed and transfected into HBE
and lung SCC cells to explore the potential biological func-
tion and underlying molecular mechanism of DDR2 and its
mutations in lung SCC development. The results showed
that ectopic expression of mutant forms of DDR2 could
function as an oncogene in either context. Further in-
vestigation indicated that enhanced DDR2 and its S131C
mutation could promote HBE and lung SCC cells prolifer-
ation, migration and invasion partly via promoting EMT
through regulating MMP-2 and E-cadherin expression.
These data indicated that mutations in discodin region
may contribute to more biologically function than muta-
tions in kinase region.
EMT is firstly recognized as a central differentiation
process allowing the remodeling of tissues during early
embryogenic and is implicated in the promotion of tumor
invasion and metastasis [20]. EMT can be initiated by
external signals originating from outside the cell, such
as transforming growth factor (TGF)-b, hepatocyte growth
factor (HGF), epidermal growth factor (EGF), and fibro-
blast growth factor (FGF) [32,33]. Furthermore, it has
been proposed and supported by numerous publications
that EMT process would be a potent mechanism that
enhances the detachment of cancer cells from primary
tumors. One characteristic of cells that undergone EMT
is the loss of E-cadherin expression, and decreased
E-cadherin expression has been reported to be associated
with poor clinical outcome in NSCLC [34,35]. Therefore,
EMT-inducing pathways may be good candidates for inter-
vention in the treatment of cancer, and it is important to
understand the molecular mechanisms that drive EMT for
the prevention of metastasis. In this study, we showed that
DDR2 and its mutation is an effective regulatory factor
promoting EMT in lung SCC cells.
Conclusions
In conclusion, the DDR2 expression pattern and muta-
tions in lung SCCs patients was observed in this study.
However, we did not evaluate the effects of expression of
mutated DDR2 in an large enough sample size to detect
a statistically significant difference in the rates of DDR2
mutation, nor did we complete an assessment of function
of all identified DDR2 mutants in lung SCC cells. Finally,
this study provides evidence that novel DDR2 mutations
in lung SCC, and at least one of which is functionally sig-
nificant adding to the knowledge of the genetic landscape
of SCCs. We hope our data may stimulate the initiation of
larger clinical trials of testing of lung SCC patients for
DDR2 mutations leading to a more effective treatment for
this deadly disease.Additional file
Additional file 1: Table S1. Clinicopathological characteristics and
DDR2 mutations of 86 patient samples of lung SCC.
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